Proteogenix는 Primary Antibody Biosimilar - Research Grade
제품을 전문적으로 생산하는 20년의 경험이 있는 High Quality 제조사입니다.
제품 설명
Amivantamab Biosimilar - Anti-EGFR, ME, RCCP2 mAb - Research Grade
제품 번호
PX-TA1576
제품 특징
Amivantamab is a bispecific monoclonal antibody with an enhanced FC-part. This antibody is part of the human immunoglobulin G1-kappa type. It is targeting epidermal growth factor receptor (EGFR) and mesenchymal epithelial transition factor (MET, a receptor tyrosine kinase). Both of these factors have key roles in proto-oncogen pathways and invasive growth program.
As Amivantamab biosimilar is targeting proto-oncogen signaling pathway, it is known to have an antineoplasic activity. Janssen Biotech has recently obtained the first approval for RYBREVANT (amivantamab-vmjw –an injection for intravenous infusion) by FDA to treat non-small cell lung cancer (NSCLC) in some conditions. There are also preregistrations in the European Union, Switzerland, Japan, China, Canada and Australia. To be used as a treatment, patients should be adults “with locally advanced or metastatic NSCLC harbouring EGFR Exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy”, according to the FDA.
NSCLC is the most common kind of primary type of lung cancer(85% of lung cancers). This cancer is mostly treated using different types of therapy such as immunotherapy and targeted therapy. NSCLCs are carcinomas: this means that the cells developing invasive growth are located on the surface of all the airway parts (bronchi, bronchioles, and alveoli). Symptoms are especially including a chronic cough, chest pain and exhaustion.
Amivantamab biosimilar is the result of about ten years of research on cross Mab technology. It is produced in mammalian cell line (Chinese Hamster Ovary -CHO) using a recombinant DNA technology. Proteogenix offers this product for research use only.
| Product name | Amivantamab Biosimilar - Anti-EGFR, ME, RCCP2 mAb - Research Grade |
| Source | CAS 2171511-58-1 |
| Species | Homo sapiens |
| Expression system | Mammalian cells |
| Purity | >85% |
| Buffer | PBS buffer PH7.5 |
| Delivery condition | Blue ice (+4°C) |
| Delivery Time | 3-5 days if in stock; 3-5 weeks if production needed |
| Storage condition | store at -80°C |
| Brand | ProteoGenix |
| Applications | ELISA, WB |
| Aliases /Synonyms | Amivantamab ,JNJ-61186372,JNJ-6372,EGFR, ME, RCCP2,anti-EGFR, ME, RCCP2 |
| Reference | PX-TA1576 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype | IgG1-kappa |
| Clonality | Monoclonal Antibody |
QC & Validation Data
Immobilized EGFR protein - Epidermal Growth Factor proteins receptor(EGFR) (cat. No.PX-P4586) at 0.5µg/mL (100µL/well) can bind to Amivantamab Biosimilar - Anti-EGFR, ME, RCCP2 mAb (cat. No.PX-TA1576) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450
ProteoGenix의 모든 제품들을 만나보세요!
Proteogenix - Official Distributor in South Korea "Morebio" 한국 독점 대리점 "모아바이오"
MSDS
온라인 견적
